US biopharma firm, TG Therapeutics, has announced an expanded contract manufacturing deal with Korea’s Samsung Biologics to support the production of its investigational anti-CD20 monoclonal antibody, ublituximab.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,